Opinion
Video
Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024
Author(s):
Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, highlighting its safety profile and 100% minimal residual disease (MRD) negativity after cycle 3, and explores how using bispecific antibodies like teclistamab earlier in treatment could influence future options for relapsed/refractory multiple myeloma.
Video content above is prompted by the following:
- Bispecific antibodies have had a significant impact on the treatment landscape for R/R multiple myeloma. Data presented at ASH is evaluating the use of bispecifics earlier in treatment. Briefly describe the data presented on MajesTEC-5, which evaluates teclistamab in combination with standard therapy in the frontline setting.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Primary end point: safety
- Secondary end point: MRD negativity, 100% after cycle 3
- How might using teclistamab in earlier lines of therapy influence treatment options in the relapsed setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
December 26th 2024
